Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2016 May 5

PMID 27142671

Citations 10

Authors

Sasha Taleban

Kathleen O Stewart

Darrick K Li

Prashant Singh

Darrell S Pardi

Holly C Sturgeon

Vijay Yajnik

Ramnik J Xavier

Ashwin N Ananthakrishnan

Hamed Khalili

Affiliations

Soon will be listed here.

Abstract

Background: Clinical activity and quality of life (QOL) indices assess disease activity in Crohn's disease (CD) and ulcerative colitis (UC). However, a paucity of data exists on the validity of these indices according to disease characteristics.

Aims: To examine the correlation between QOL and clinical activity indices and endoscopic disease activity according to disease characteristics.

Methods: We used a prospective registry to identify CD and UC patients ≥18 years old with available information on Short Inflammatory Bowel Disease Questionnaire scores (SIBDQ), Harvey-Bradshaw Index (HBI) and simple endoscopic scores for CD (SES-CD), and Simple Clinical Colitis Activity Index (SCCAI) and Mayo endoscopic score for UC. We used Spearman rank correlations to calculate correlations between indices and Fisher transformation to compare correlations across disease characteristics.

Results: Among 282 CD patients, we observed poor correlation between clinical activity and QOL indices to SES-CD with no differences in correlation according to disease characteristics. Conversely, among 226 UC patients, clinical activity and QOL had good correlation to Mayo endoscopic score (r = 0.55 and -0.56, respectively) with better correlations observed with left-sided versus extensive colitis (r = 0.73 vs. 0.45, p = 0.005) and shorter duration of disease (r = 0.61 vs. 0.37, p = 0.04).

Conclusions: Our data suggest good correlation between SCCAI and endoscopic disease activity in UC, particularly in left-sided disease. Poor correlations between HBI or SIBDQ and SES-CD appear to be consistent across different disease phenotypes.

Citing Articles

Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From the CorEvitas Inflammatory Bowel Disease Registry.

Wolf D, Naegeli A, Moore P, Janak J, Crabtree M, Shan M Gastro Hep Adv. 2024; 2(6):799-809.

PMID: 39130112 PMC: 11308049. DOI: 10.1016/j.gastha.2023.03.024.

Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients.

Naegeli A, Hunter T, Dong Y, Hoskin B, Middleton-Dalby C, Hetherington J Crohns Colitis 360. 2023; 3(1):otab007.

PMID: 36777063 PMC: 9802037. DOI: 10.1093/crocol/otab007.

The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Yarlas A, Willian M, Nag A Qual Life Res. 2021; 30(7):1925-1938.

PMID: 33651279 PMC: 8233235. DOI: 10.1007/s11136-021-02787-4.

The introduction of the IBD Disk in Poland - a new tool for assessing disability in patients with inflammatory bowel disease.

Eder P, Liebert A, Lodyga M, Kaniewska M, Klopocka M, Rydzewska G Prz Gastroenterol. 2020; 15(1):55-59.

PMID: 32215129 PMC: 7089864. DOI: 10.5114/pg.2019.85337.

Comparison of Lewis Score and Capsule Endoscopy Crohn's Disease Activity Index in Patients with Crohn's Disease.

Omori T, Kambayashi H, Murasugi S, Ito A, Yonezawa M, Nakamura S Dig Dis Sci. 2019; 65(4):1180-1188.

PMID: 31541367 DOI: 10.1007/s10620-019-05837-7.

References

Casellas F, Alcala M, Prieto L, Miro J, Malagelada J . Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004; 99(3):457-61. DOI: 10.1111/j.1572-0241.2004.04071.x. View

Loftus Jr E, Silverstein M, Sandborn W, Tremaine W, Harmsen W, Zinsmeister A . Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000; 46(3):336-43. PMC: 1727835. DOI: 10.1136/gut.46.3.336. View

Veloso F, Ferreira J, Barros L, Almeida S . Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis. 2001; 7(4):306-13. DOI: 10.1097/00054725-200111000-00005. View

Ricanek P, Brackmann S, Perminow G, Lyckander L, Sponheim J, Holme O . Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011; 46(9):1081-91. DOI: 10.3109/00365521.2011.584897. View

Casellas F, Lopez-Vivancos J, Casado A, Malagelada J . Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 2002; 11(8):775-81. DOI: 10.1023/a:1020841601110. View

Gerich M, McGovern D . Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol. 2013; 11(5):287-99. DOI: 10.1038/nrgastro.2013.242. View

Shen B, Fazio V, Remzi F, Bennett A, Lavery I, Lopez R . Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch. Dis Colon Rectum. 2007; 50(9):1450-9. DOI: 10.1007/s10350-007-0284-8. View

Seo M, Okada M, Maeda K, Oh K . Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol. 1998; 93(11):2124-9. DOI: 10.1111/j.1572-0241.1998.00607.x. View

Yang D, Yang S, Park S, Lee H, Boo S, Park J . Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. Gut Liver. 2014; 9(1):80-6. PMC: 4282861. DOI: 10.5009/gnl13424. View

10.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

11.

Yarur A, Abreu M, Salem M, Deshpande A, Sussman D . The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci. 2013; 59(1):126-34. DOI: 10.1007/s10620-013-2603-3. View

12.

Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Farkkila M . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2007; 14(1):40-6. DOI: 10.1002/ibd.20312. View

13.

Colombel J, Rutgeerts P, Sandborn W, Yang M, Camez A, Pollack P . Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013; 12(3):414-22.e5. DOI: 10.1016/j.cgh.2013.06.019. View

14.

Voiosu T, Bengus A, Dinu R, Voiosu A, Balanescu P, Baicus C . Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. J Gastrointestin Liver Dis. 2014; 23(3):273-8. DOI: 10.15403/jgld.2014.1121.233.thv. View

15.

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

16.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

17.

Loftus Jr E, Silverstein M, Sandborn W, Tremaine W, Harmsen W, Zinsmeister A . Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998; 114(6):1161-8. DOI: 10.1016/s0016-5085(98)70421-4. View

18.

Ghazi L, Lydecker A, Patil S, Rustgi A, Cross R, Flasar M . Racial differences in disease activity and quality of life in patients with Crohn's disease. Dig Dis Sci. 2014; 59(10):2508-13. DOI: 10.1007/s10620-014-3141-3. View

19.

Bodger K, Ormerod C, Shackcloth D, Harrison M . Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut. 2013; 63(7):1092-102. PMC: 4078750. DOI: 10.1136/gutjnl-2013-305600. View

20.

Colombel J, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y . Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141(4):1194-201. DOI: 10.1053/j.gastro.2011.06.054. View